Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H18ClFN6O2.C6H6O3S |
Molecular Weight | 599.033 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(=O)(=O)C1=CC=CC=C1.CN2N=CC=C2NC3=NC(=CC=N3)C4=CC(=O)N(C=C4)[C@H](CO)C5=CC=C(Cl)C(F)=C5
InChI
InChIKey=TWSFAQBOAWKKIH-GMUIIQOCSA-N
InChI=1S/C21H18ClFN6O2.C6H6O3S/c1-28-19(5-8-25-28)27-21-24-7-4-17(26-21)13-6-9-29(20(31)11-13)18(12-30)14-2-3-15(22)16(23)10-14;7-10(8,9)6-4-2-1-3-5-6/h2-11,18,30H,12H2,1H3,(H,24,26,27);1-5H,(H,7,8,9)/t18-;/m1./s1
Molecular Formula | C21H18ClFN6O2 |
Molecular Weight | 440.858 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C6H6O3S |
Molecular Weight | 158.175 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=1eb84585-6831-405d-88b2-cef74aaf004e&cKey=22cc177f-4718-4f12-bdf6-a275db718f29&mKey=6ffe1446-a164-476a-92e7-c26446874d93 | https://www.ncbi.nlm.nih.gov/pubmed/27227380
Curator's Comment: description was created based on several sources, including:
http://www.abstractsonline.com/Plan/ViewAbstract.aspx?mID=3404&sKey=1eb84585-6831-405d-88b2-cef74aaf004e&cKey=22cc177f-4718-4f12-bdf6-a275db718f29&mKey=6ffe1446-a164-476a-92e7-c26446874d93 | https://www.ncbi.nlm.nih.gov/pubmed/27227380
GDC-0994 (RG7842) is a selective inhibitor of ERK1/2, also known as extracellular-signal-regulated kinases. Daily, oral dosing of GDC-0994 results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. GDC-0994 neither increases nor decreases phospho-ERK, suggesting that different ERK inhibitors have alternative mechanisms of action with respect to feedback signaling. GDC-0994 is currently advancing in a Phase 1 trial in patients with solid tumors.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3385 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27227380 |
6.1 nM [IC50] | ||
Target ID: CHEMBL4040 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27227380 |
3.1 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10.7 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1.66 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.68 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
5.17 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
7.57 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.88 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
179 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
800 mg 1 times / day multiple, oral dose: 800 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
26.8 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
62 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
88.9 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
400 mg 1 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
129 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
27.7 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/31848189/ |
100 mg 1 times / day multiple, oral dose: 100 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RAVOXERTINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27227380
Once daily on a 21-day on/7 day off schedule. Dose from 50 to 200 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27227380
GDC-0994 inhibits the ERK-dependent p90RSK Serine 380 phosphorylation in PMA-stimulated HepG2 cells (IC50=12nM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:24:09 UTC 2023
by
admin
on
Sat Dec 16 09:24:09 UTC 2023
|
Record UNII |
TMG3621R53
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
91971355
Created by
admin on Sat Dec 16 09:24:09 UTC 2023 , Edited by admin on Sat Dec 16 09:24:09 UTC 2023
|
PRIMARY | |||
|
1817728-45-2
Created by
admin on Sat Dec 16 09:24:09 UTC 2023 , Edited by admin on Sat Dec 16 09:24:09 UTC 2023
|
PRIMARY | |||
|
TMG3621R53
Created by
admin on Sat Dec 16 09:24:09 UTC 2023 , Edited by admin on Sat Dec 16 09:24:09 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |